Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Iterum Therapeutics stock

Learn how to easily invest in Iterum Therapeutics stock.

Iterum Therapeutics PLC is a biotechnology business based in the US. Iterum Therapeutics shares (ITRM) are listed on the NASDAQ and all prices are listed in US Dollars. Iterum Therapeutics employs 13 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Iterum Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ITRM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Iterum Therapeutics stock price (NASDAQ: ITRM)

Use our graph to track the performance of ITRM stocks over time.

Iterum Therapeutics shares at a glance

Information last updated 2022-07-02.
Latest market close$0.21
52-week range$0.18 - $1.49
50-day moving average $0.23
200-day moving average $0.39
Wall St. target price$1.00
PE ratio 0.8536
Dividend yield $0 (0%)
Earnings per share (TTM) $0.25

Buy Iterum Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you open a Robinhood account
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Iterum Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Iterum Therapeutics price performance over time

Historical closes compared with the close of $0.213 from 2022-07-01

1 week (2022-06-29) -3.66%
1 month (2022-06-06) -5.79%
3 months (2022-04-05) -37.81%
6 months (2022-01-06) -48.05%
1 year (2021-07-06) -83.36%
2 years (2020-07-06) -81.95%
3 years (2019-07-03) 6.64
5 years (2017-07-02) N/A

Is Iterum Therapeutics stock undervalued or overvalued?

Valuing Iterum Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Iterum Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Iterum Therapeutics's P/E ratio

Iterum Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Iterum Therapeutics shares trade at around 1x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Iterum Therapeutics financials

Gross profit TTM $37,000
Return on assets TTM -16.35%
Return on equity TTM 9.62%
Profit margin 0%
Book value $0.27
Market capitalisation $39.1 million

TTM: trailing 12 months

Iterum Therapeutics share dividends

We're not expecting Iterum Therapeutics to pay a dividend over the next 12 months.

Iterum Therapeutics share price volatility

Over the last 12 months, Iterum Therapeutics's shares have ranged in value from as little as $0.175 up to $1.49. A popular way to gauge a stock's volatility is its "beta".

ITRM.US volatility(beta: 1.2)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Iterum Therapeutics's is 1.2017. This would suggest that Iterum Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Iterum Therapeutics overview

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. .

Frequently asked questions

What percentage of Iterum Therapeutics is owned by insiders or institutions?
Currently 0.84% of Iterum Therapeutics shares are held by insiders and 3.459% by institutions.
How many people work for Iterum Therapeutics?
Latest data suggests 13 work at Iterum Therapeutics.
When does the fiscal year end for Iterum Therapeutics?
Iterum Therapeutics's fiscal year ends in December.
Where is Iterum Therapeutics based?
Iterum Therapeutics's address is: Fitzwilliam Court, Dublin, Ireland, 2
What is Iterum Therapeutics's ISIN number?
Iterum Therapeutics's international securities identification number is: IE00BF3W0Q35
What is Iterum Therapeutics's CUSIP number?
Iterum Therapeutics's Committee on Uniform Securities Identification Procedures number is: G6333L101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site